Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, for relapsed or refractory NHL patients

British Journal of Haematology

Volumn 168, Issue 1, 2015, Pages 38-45

  Pagel, John M ^a   Spurgeon, Stephen E ^b   Byrd, John C ^c   Awan, Farrukh T ^d   Flinn, Ian W ^e   Lanasa, Mark C ^f   Eisenfeld, Amy J ^g   Stromatt, Scott C ^g   Gopal, Ajay K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g Emergent Product Development   (United States)

Author keywords

AntiCD37; Clinical trial; Non Hodgkin lymphoma; Otlertuzumab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALLOPURINOL; ASPARTATE AMINOTRANSFERASE; DIPHENHYDRAMINE; HYDROCORTISONE; OTLERTUZUMAB; PARACETAMOL; VALACICLOVIR; ANTINEOPLASTIC AGENT; CD37 PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN G; TETRASPANIN; TUMOR ANTIGEN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW BIOPSY; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NIGHT SWEAT; NONHODGKIN LYMPHOMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REFRACTORY PERIOD; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RECURRENCE; TETRASPANINS; TREATMENT OUTCOME;

EID: 84915788744     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13099     Document Type: Article

References (32)

1. TM Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma. Blood, 116, 3931.
2. Barrena, S., Almeida, J., Yunta, M., Lopez, A., Fernandez-Mosteirin, N., Giralt, M., Romero, M., Perdiguer, L., Delgado, M., Orfao, A. & Lazo, P.A. (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia, 19, 1376-1383.
3. Baum, P.R., Cerveny, C., Gordon, B., Nilsson, C., Wiens, J., Rafiq, S., Lapalombella, R., Muthusamy, N., Byrd, J.C. & Wahl, A. (2009) Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 27, 8571.
4. Belov, L., de la Vega, O., dos Remedios, C.G., Mulligan, S.P. & Christopherson, R.I. (2001) Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Research, 61, 4483-4489.
5. Byrd, J.C., Pagel, J.M., Awan, F.T., Forero, A., Flinn, I.W., Deauna-Limayo, D.P., Spurgeon, S.E., Andritsos, L.A., Gopal, A.K., Leonard, J.P., Eisenfeld, A.J., Bannink, J.E., Stromatt, S.C. & Furman, R.R. (2014) A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood, 123, 1302-1308.
6. Campo, E., Cardesa, A., Alos, L., Palacin, A., Cobarro, J., Traserra, J. & Montserrat, E. (1991) Non-Hodgkin's lymphomas of nasal cavity and paranasal sinuses. An immunohistochemical study. American Journal of Clinical Pathology, 96, 184-190.
7. Carbone, A., Pinto, A., Gloghini, A., Volpe, R. & Zagonel, V. (1992) B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders. Human Pathology, 23, 438-448.
8. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M., Diehl, V. & International Harmonization Project on Lymphoma. (2007). Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
9. Coiffier, B. (2002) Rituximab in the treatment of diffuse large B-cell lymphomas. Seminars in oncology, 29, 30-35.
10. Coiffier, B. (2004) Rituximab in diffuse large B-cell lymphoma. Clinical Advances in Hematolology and Oncology, 2, 156-157.
11. Coiffier, B. (2007) Rituximab therapy in malignant lymphoma. Oncogene, 26, 3603-3613.
12. Ellis, S., Carroll, K.J. & Pemberton, K. (2008) Analysis of duration of response in oncology trials. Contemporary Clinical Trials, 29, 456-465.
13. Jilani, I., O'Brien, S., Manshuri, T., Thomas, D.A., Thomazy, V.A., Imam, M., Naeem, S., Verstovsek, S., Kantarjian, H., Giles, F., Keating, M. & Albitar, M. (2003) Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood, 102, 3514-3520.
14. Kaminski, M.S., Fig, L.M., Zasadny, K.R., Koral, K.F., DelRosario, R.B., Francis, I.R., Hanson, C.A., Normolle, D.P., Mudgett, E. & Liu, C.P. (1992) Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. Journal of Clinical Oncology, 10, 1696-1711.
15. Kennedy, A.D., Solga, M.D., Schuman, T.A., Chi, A.W., Lindorfer, M.A., Sutherland, W.M., Foley, P.L. & Taylor, R.P. (2003) An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20 + cells by rituximab. Blood, 101, 1071-1079.
16. Lapalombella, R., Yeh, Y.Y., Wang, L., Ramanunni, A., Rafiq, S., Jha, S., Staubli, J., Lucas, D.M., Mani, R., Herman, S.E., Johnson, A.J., Lozanski, A., Andritsos, L., Jones, J., Flynn, J.M., Lannutti, B., Thompson, P., Algate, P., Stromatt, S., Jarjoura, D., Mo, X., Wang, D., Chen, C.S., Lozanski, G., Heerema, N.A., Tridandapani, S., Freitas, M.A., Muthusamy, N. & Byrd, J.C. (2012) Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell, 21, 694-708.
17. Leshchenko, V.V., Kuo, P.Y., Shaknovich, R., Yang, D.T., Gellen, T., Petrich, A., Yu, Y., Remache, Y., Weniger, M.A., Rafiq, S., Suh, K.S., Goy, A., Wilson, W., Verma, A., Braunschweig, I., Muthusamy, N., Kahl, B.S., Byrd, J.C., Wiestner, A., Melnick, A. & Parekh, S. (2010) Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood, 116, 1025-1034.
18. Leveque, D., Wisniewski, S. & Jehl, F. (2005) Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Research, 25, 2327-2343.
19. Link, M.P., Bindl, J., Meeker, T.C., Carswell, C., Doss, C.A., Warnke, R.A. & Levy, R. (1986) A unique antigen on mature B cells defined by a monoclonal antibody. Journal of Immunology, 137, 3013-3018.
20. Moore, K., Cooper, S.A. & Jones, D.B. (1987) Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. The Journal of Pathology, 152, 13-21.
21. Norton, A.J. & Isaacson, P.G. (1987) Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. The American journal of Pathology, 128, 225-240.
22. Owen, R.G., Kyle, R.A., Stone, M.J., Rawstron, A.C., Leblond, V., Merlini, G., Garcia-Sanz, R., Ocio, E.M., Morra, E., Morel, P., Anderson, K.C., Patterson, C.J., Munshi, N.C., Tedeschi, A., Joshua, D.E., Kastritis, E., Terpos, E., Ghobrial, I.M., Leleu, X., Gertz, M.A., Ansell, S.M., Morice, W.G., Kimby, E., Treon, S.P. & VIth International Workshop on Waldenström macroglobulinaemia. (2013). Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. British Journal of Haematology, 160, 171-176.
23. Picker, L.J., Weiss, L.M., Medeiros, L.J., Wood, G.S. & Warnke, R.A. (1987) Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. The American Journal of Pathology, 128, 181-201.
24. Press, O.W., Eary, J.F., Badger, C.C., Martin, P.J., Appelbaum, F.R., Levy, R., Miller, R., Brown, S., Nelp, W.B. & Krohn, K.A. (1989) Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. Journal of Clinical Oncology, 7, 1027-1038.
25. Rezvani, A.R. & Maloney, D.G. (2011) Rituximab resistance. Best Practice & Research. Clinical Haematology, 24, 203-216.
26. Schuurman, H.J., van Baarlen, J., Huppes, W., Lam, B.W., Verdonck, L.F. & van Unnik, J.A. (1987) Immunophenotyping of non-Hodgkin's lymphoma. Lack of correlation between immunophenotype and cell morphology. The American Journal of Pathology, 129, 140-151.
27. Schwartz-Albiez, R., Dorken, B., Hofmann, W. & Moldenhauer, G. (1988) The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. Journal of Immunology, 140, 905-914.
28. al-Sharabati, M., Chittal, S., Duga-Neulat, I., Laurent, G., Mazerolles, C., al-Saati, T., Brousset, P. & Delsol, G. (1991).Primary anterior mediastinal B-cell lymphoma. A clinicopathologic and immunohistochemical study of 16 cases. Cancer, 67, 2579-2587.
29. Smith, J.L., Jones, D.B., Bell, A.J. & Wright, D.H. (1989) Correlation between histology and immunophenotype in a series of 322 cases of non-Hodgkin's lymphoma. Hematological Oncology, 7, 37-48.
30. Treon, S.P., Gertz, M.A., Dimopoulos, M., Anagnostopoulos, A., Blade, J., Branagan, A.R., Garcia-Sanz, R., Johnson, S., Kimby, E., Leblond, V., Fermand, J.P., Maloney, D.G., Merlini, G., Morel, P., Morra, E., Nichols, G., Ocio, E.M., Owen, R. & Stone, M.J. (2006) Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood, 107, 3442-3446.
31. Wendtner, C.M. (2014) Otlertuzumab more than a TRU(E) toddler in CLL? Blood, 123, 1282-1284.
32. Zhao, X., Lapalombella, R., Joshi, T., Cheney, C., Gowda, A., Hayden-Ledbetter, M.S., Baum, P.R., Lin, T.S., Jarjoura, D., Lehman, A., Kussewitt, D., Lee, R.J., Caligiuri, M.A., Tridandapani, S., Muthusamy, N. & Byrd, J.C. (2007) Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood, 110, 2569-2577.